REGISTER NOW TO BECOME A MEMBER

You are viewing the 1st of the 2 courses UPMC Physician Resources permits you to view without registering. To have full access to our FREE courses on our website, please register or log in now.
Register

In this CME, Eileen M. O'Reilly, MD, Susannah Ellsworth, MD, Amer H. Zureikat, MD, and Alessandro Paniccia, MD, discuss the most common indications for radiotherapy in pancreatic cancer, the main modalities of radiotherapy used for treatment of pancreatic cancer, and review data supporting integration of SBRT into multimodality pancreatic cancer treatment regimens. 

Educational Objectives 

Upon completion of this activity, participants should be able to:

  • Recognize the most common indications for radiotherapy in pancreatic cancer
  • Identify main modalities of RT used for treatment of pancreatic cancer including 3-D conformal, intensity-modulated, and stereotactic body radiation therapy
  • Identify main indications and contraindications for stereotactic body radiation therapy in pancreatic cancer
  • Analyze data supporting integration of SBRT into multimodality pancreatic cancer treatment regimens in order to identify patients who may benefit from this treatment

Disclosures:

All individuals in a position to control the content of this education activity have disclosed all financial relationships with any companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All of the relevant financial relationships for the individuals listed below have been mitigated

Dr. Gallinger has financial interests with the following entity or entities producing health care goods or services as indicated below:

  • Consultant: Cellular Analytics

Dr. O’Reilly has financial interests with the following entity or entities producing health care goods or services as indicated below:

  • Grant/Research Support: Arcus, AstraZeneca, BioNTech, Celgene/BMS, Elicit, Genentech/Roche, and Parker Institute.
  • Consultant: AstraZeneca, Bayer (spouse), BioNTech, BioSapien, Boehringer Ingelheim, Celgene/BMS (spouse), Cend Therapeutics, Cytomx Therapeutics (DSMB), Eisai (spouse), Genentech/Roche (spouse), IDEAYA, Ipsen, Merck, Noxxon, Rafael Therapeutics (DSMB), Seagen, Silenseed, Thetis, and Time.

No other members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships with any companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Accreditation Statement

In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Pittsburgh designates enduring material activity for a maximum of 2.0 AMA PRA Category 1 Credit[s]™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.

For your credit transcript, please access our website 4 weeks post-completion at http://ccehs.upmc.com and follow the link to the Credit Transcript page. If you do not provide the last 5 digits of your SSN on the next page you will not be able to access a CME credit transcript. Providing your SSN is voluntary.

Release Date: 4/14/2022 | Last Modified On: 4/14/2022 | Expires: 4/14/2023

take cme evaluation